Cinacalcet Improves Control of Secondary Hyperparathyroidism in Peritoneal Dialysis: A Multicenter Study
- 1 March 2012
- journal article
- research article
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 32 (2) , 208-211
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Simultaneous Control of PTH and Ca×P Is Sustained over Three Years of Treatment with Cinacalcet HClClinical Journal of the American Society of Nephrology, 2009
- Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational studyNephrology Dialysis Transplantation, 2009
- K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patientsKidney International, 2008
- The OPTIMA StudyClinical Journal of the American Society of Nephrology, 2008
- Meta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic TherapyAmerican Journal of Kidney Diseases, 2006
- The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association With Mortality in Dialysis PatientsAmerican Journal of Kidney Diseases, 2005
- Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving HemodialysisNew England Journal of Medicine, 2004
- K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.2003
- Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTHKidney International, 1995